Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 2% – What’s Next?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) shares traded up 2% during trading on Monday . The company traded as high as $6.32 and last traded at $6.12. 33,255 shares traded hands during mid-day trading, a decline of 34% from the average session volume of 50,205 shares. The stock had previously closed at $6.00.

Analyst Upgrades and Downgrades

Separately, Jones Trading started coverage on Armata Pharmaceuticals in a research note on Monday, January 5th. They issued a “buy” rating and a $15.00 target price for the company. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Armata Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $12.00.

Armata Pharmaceuticals Price Performance

The company’s 50-day moving average price is $6.35 and its 200-day moving average price is $4.45. The company has a market cap of $222.83 million, a P/E ratio of -3.78 and a beta of 1.29.

Institutional Trading of Armata Pharmaceuticals

A hedge fund recently raised its stake in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC increased its position in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 17.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 40,988 shares of the company’s stock after buying an additional 6,034 shares during the quarter. SeaCrest Wealth Management LLC owned 0.11% of Armata Pharmaceuticals worth $274,000 as of its most recent SEC filing. 3.57% of the stock is currently owned by institutional investors and hedge funds.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.